Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform

We herein report the development and evaluation of a novel HER2-targeting antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in vivo experiments were conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Conilh, Louise, Fournet, Guy, Fourmaux, Eric, Murcia, Angélique, Matera, Eva-Laure, Joseph, Benoît, Dumontet, Charles, Viricel, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000490/
https://www.ncbi.nlm.nih.gov/pubmed/33803327
http://dx.doi.org/10.3390/ph14030247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000490/
https://www.ncbi.nlm.nih.gov/pubmed/33803327
http://dx.doi.org/10.3390/ph14030247

Ejemplares similares